Louisiana State Employees Retirement System Has $1.65 Million Stake in Bio-Rad Laboratories, Inc. (BIO)

Louisiana State Employees Retirement System lifted its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 1.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,400 shares of the medical research company’s stock after buying an additional 100 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Bio-Rad Laboratories were worth $1,651,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently modified their holdings of the company. Virtu Financial LLC acquired a new stake in shares of Bio-Rad Laboratories in the first quarter worth $1,655,000. First Citizens Bank & Trust Co. lifted its stake in shares of Bio-Rad Laboratories by 38.0% in the first quarter. First Citizens Bank & Trust Co. now owns 1,720 shares of the medical research company’s stock worth $526,000 after buying an additional 474 shares during the last quarter. CenturyLink Investment Management Co lifted its stake in shares of Bio-Rad Laboratories by 15.7% in the first quarter. CenturyLink Investment Management Co now owns 4,935 shares of the medical research company’s stock worth $1,509,000 after buying an additional 669 shares during the last quarter. BTR Capital Management Inc. lifted its stake in shares of Bio-Rad Laboratories by 5.1% in the first quarter. BTR Capital Management Inc. now owns 3,120 shares of the medical research company’s stock worth $954,000 after buying an additional 150 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Bio-Rad Laboratories by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 214,188 shares of the medical research company’s stock worth $49,738,000 after buying an additional 15,557 shares during the last quarter. Institutional investors and hedge funds own 63.63% of the company’s stock.

A number of equities analysts recently issued reports on BIO shares. Deutsche Bank boosted their target price on shares of Bio-Rad Laboratories from $330.00 to $350.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Zacks Investment Research raised shares of Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a research report on Friday, February 22nd. Finally, Barclays boosted their target price on shares of Bio-Rad Laboratories from $315.00 to $340.00 and gave the stock an “overweight” rating in a research report on Friday, March 1st. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Bio-Rad Laboratories presently has a consensus rating of “Buy” and an average target price of $359.17.

Shares of BIO stock opened at $301.44 on Wednesday. Bio-Rad Laboratories, Inc. has a 1 year low of $220.05 and a 1 year high of $345.15. The firm has a market cap of $9.14 billion, a P/E ratio of 52.43, a P/E/G ratio of 2.86 and a beta of 1.27. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.19 and a current ratio of 4.49.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Thursday, February 28th. The medical research company reported $2.13 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.61 by $0.52. The business had revenue of $617.54 million for the quarter, compared to analyst estimates of $610.65 million. Bio-Rad Laboratories had a net margin of 15.76% and a return on equity of 3.92%. Analysts predict that Bio-Rad Laboratories, Inc. will post 7.16 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Louisiana State Employees Retirement System Has $1.65 Million Stake in Bio-Rad Laboratories, Inc. (BIO)” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://sportsperspectives.com/2019/04/17/louisiana-state-employees-retirement-system-has-1-65-million-stake-in-bio-rad-laboratories-inc-bio.html.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Read More: What is Net Asset Value (NAV)?

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.